Revolution Medicines' net loss widens 160% to -$644.4M as operating loss grows 91%

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~1 min read

Key Changes

• high

  Net loss widened 160.1% to $644.4M, far outpacing the 90.8% increase in operating loss to $505.1M, driven by a larger below-the-line deduction (taxes/interest/warrant liability) rather than operations.

  MD&A: Results of Operations verify on EDGAR →
• high

  Daraxonrasib achieved positive Phase 3 RASolute 302 results (median OS 13.2 vs 6.7 months, HR 0.40) and received FDA acceptance of its NDA for previously treated metastatic pancreatic cancer.

  MD&A: Pipeline verify on EDGAR →
• high

  Company raised ~$2.2B in April 2026 via a $1.65B follow-on equity offering and $500M convertible notes, boosting cash to $3.9B.

  MD&A: Liquidity verify on EDGAR →